Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million. In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 8.88% and total debt rose 294.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow SRRK
Scholar Rock Holding Corporation (SRRK) Piotroski F-score
Scholar Rock Holding Corporation's Piotroski F-score for fiscal 2022 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, up from 2 in fiscal 2021.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 3 | 1.00 |
| FY2021 | 2 | — |
How fiscal 2022’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (40.60%) | (38.05%) | Fail | 0 |
| Positive operating cash flow | (132.69m) | (126.79m) | Fail | 0 |
| Rising return on assets | (40.60%) | (38.05%) | Fail | 0 |
| Cash flow above net income | 1.81m | 5.01m | Pass | 1 |
| Falling long-term leverage | 0.15 | 0.14 | Fail | 0 |
| Rising current ratio | 9.01 | 4.13 | Pass | 1 |
| No new shares issued | 59,612,000 | 36,712,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.10 | 0.05 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 7 |
| TVTX Travere Therapeutics, Inc. compare | 6 |
| MIRM Mirum Pharmaceuticals, Inc. compare | 6 |
| COGT Cogent Biosciences, Inc. compare | 3 |
| SRRK Scholar Rock Holding Corporation | 3 |
| CRSP CRISPR Therapeutics AG compare | 2 |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover